Furegrelate sodium

Research use only, not for human use.

Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity.

Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.(In Vivo):Furegrelate sodium has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs) and reportedly is highly specific for its target enzyme. Furegrelate sodium (1-5 mg/kg; oral) prevents blockage of the coronary artery. Furegrelate sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused by platelet aggregation. Furegrelate sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.

——

Animal Model:Mongrel dogs (19-30 kg)Dosage:1-5 mg/kg Administration:Oral (via a gastric tube)Result:Prevented blockage of the coronary artery.

U-63557A

Metabolic Enzyme/Protease

PPAR

B-Raf (V600E)

——

——

85666-17-7

275.239

C15H10NNaO3

>98% (HPLC)

In Vitro:?DMSO : 13 mg/mL (47.23 mM)

[Na]OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1

——

(-20℃)

With Ice Pack

≥ 2 years